These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38293718)

  • 1. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.
    Lavrado NC; Salles GF; Cardoso CRL; de França PHC; Melo MFDGG; Leite NC; Villela-Nogueira CA
    Liver Int; 2024 Apr; 44(4):1042-1050. PubMed ID: 38293718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C.
    Oliveira AIN; Malta FM; Zitelli PMY; Salles APM; Gomes-Gouvea MS; Nastri ACS; Pinho JRR; Carrilho FJ; Oliveira CP; Mendes-Corrêa MC; Pessoa MG; Mazo DF
    BMC Gastroenterol; 2021 Feb; 21(1):81. PubMed ID: 33622266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of
    Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?
    Agoglia L; Cardoso AC; Barbosa L; Victer CSXL; Carneiro S; de França PHC; Chindamo MC; Villela-Nogueira CA
    Ann Hepatol; 2024; 29(4):101477. PubMed ID: 38360269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.
    Rashu EB; Werge MP; Hetland LE; Thing M; Nabilou P; Kimer N; Junker AE; Jensen AH; Nordestgaard BG; Stender S; Gluud LL
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102389. PubMed ID: 38830575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation between PNPLA3 rs738409 and TM6SF2 rs58542926 gene polymorphism and primary liver cancer in the Han Population of China's Northeast region].
    Bing H; Wang W; Li YL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):156-162. PubMed ID: 33685085
    [No Abstract]   [Full Text] [Related]  

  • 8. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PNPLA3 risk allele is associated with risk of hepatocellular carcinoma but not decompensation in compensated cirrhosis.
    Urias E; Tedesco NR; Burkholder DA; Moran IJ; Miller MJ; Jasty VSJ; Patil S; Zoellner S; Wijarnpreecha K; Chen VL
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease?
    Machado CM; Leite NC; França PH; Cardoso CR; Salles GF; Villela-Nogueira CA
    Nutr Metab Cardiovasc Dis; 2019 Sep; 29(9):965-971. PubMed ID: 31377187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.
    Rauff B; Alzahrani B; Chudhary SA; Nasir B; Mahmood S; Bhinder MA; Faheem M; Amar A
    BMC Gastroenterol; 2022 Aug; 22(1):401. PubMed ID: 36028802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parental History of Type 2 Diabetes Mellitus and PNPLA3 Polymorphism Increase the Risk of Severe Stages of Nonalcoholic Fatty Liver Disease.
    Wajsbrot NB; Leite NC; Franca PHC; Cardoso CRL; Salles GF; Villela-Nogueira CA
    Dig Dis Sci; 2024 Feb; 69(2):634-642. PubMed ID: 38112841
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C.
    Manchiero C; Nunes AKDS; Magri MC; Dantas BP; Mazza CC; Barone AA; Tengan FM
    BMC Infect Dis; 2017 Dec; 17(1):780. PubMed ID: 29258449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
    Kruk B; Liebe R; Milkiewicz M; Wunsch E; Raszeja-Wyszomirska J; Lammert F; Milkiewicz P; Krawczyk M
    PLoS One; 2018; 13(8):e0202942. PubMed ID: 30161167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Seko Y; Yamaguchi K; Shima T; Iwaki M; Takahashi H; Kawanaka M; Tanaka S; Mitsumoto Y; Yoneda M; Nakajima A; Okanoue T; Itoh Y
    Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1436-1443.e4. PubMed ID: 38604296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD.
    Jarasvaraparn C; Vilar-Gomez E; Yates KP; Wilson LA; Neuschwander-Tetri B; Loomba R; Cummings O; Vos M; Xanthakos S; Schwimmer J; Molleston JP; Sanyal A; Tonascia J; Chalasani N
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1024-1036.e2. PubMed ID: 38145725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.